299. 嚢胞性線維症 Cystic fibrosis Clinical trials / Disease details
臨床試験数 : 1,696 / 薬物数 : 1,644 - (DrugBank : 272) / 標的遺伝子数 : 96 - 標的パスウェイ数 : 170
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02707562 (ClinicalTrials.gov) | February 2016 | 22/2/2016 | Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation) | A Phase IIa, Open-label Study of Multiple Doses of GLPG1837 in Subjects With Cystic Fibrosis and the G551D Mutation | Cystic Fibrosis | Drug: GLPG1837 dose 1;Drug: GLPG1837 dose 2;Drug: GLPG1837 dose 3 | Galapagos NV | NULL | Completed | 18 Years | N/A | Both | 26 | Phase 2 | Australia;Czech Republic;Germany;Ireland;United Kingdom |
| 2 | NCT02690519 (ClinicalTrials.gov) | January 2016 | 16/2/2016 | Study of GLPG1837 in Subjects With Cystic Fibrosis (S1251N Mutation) | A Phase IIa, Open-label Study of Two Doses of GLPG1837 in Subjects With Cystic Fibrosis and the S1251N Mutation | Cystic Fibrosis | Drug: GLPG1837 dose 1;Drug: GLPG1837 dose 2 | Galapagos NV | NULL | Completed | 18 Years | N/A | Both | 7 | Phase 2 | Belgium;Netherlands |